Ivan Kairatov is a leading biopharma expert with a deep specialization in the metabolic pathways that govern cancer progression and therapeutic resistance. With years of experience in research and development, Kairatov has focused on how innovation in the industry can sometimes clash with traditional treatment protocols, particularly when popular health trends overlap with oncology. His insights are crucial for understanding how seemingly beneficial molecules like NAD+ can be repurposed by tumors to bypass the lethal effects of modern medicine.
The following discussion explores the hidden dangers of vitamin B3 derivatives, such as NMN and NR, during active cancer treatment. We delve into the metabolic hijacking of energy precursors by pancreatic cancer cells, the biochemical interference these supplements cause with oxidative stress-inducing therapies, and the urgent need for clinical protocols to screen for supplement use in oncology settings.
NAD+ is a fundamental molecule used for energy production in all cell types. How do cancer cells specifically hijack these precursors to resist drugs like gemcitabine, and what metabolic metrics should clinicians monitor to identify this survival strategy?
In the high-stakes environment of a tumor, cancer cells act as metabolic scavengers that aggressively consume any available fuel to ensure their survival. When we introduce NAD+ precursors like nicotinamide riboside or NMN, we are essentially flooding the cellular environment with high-octane energy that tumors utilize to repair the specific DNA damage caused by gemcitabine. By boosting their internal energy systems, these cells become resilient enough to avoid the programmed cell death that chemotherapy is designed to trigger. Clinicians should be particularly vigilant about monitoring markers of cellular metabolic activity and DNA repair efficiency, as these can signal when a tumor has effectively “armored” itself against treatment. In our laboratory models, we have seen that this influx of fuel allows tumors to survive doses of chemotherapy that should, by all biological standards, be lethal.
Standard therapies like oxaliplatin and 5-fluorouracil rely on inducing oxidative stress and DNA damage to eliminate tumors. When patients introduce vitamin B3 derivatives, how do these supplements neutralize those mechanisms, and what specific biological pathways are being reinforced?
Chemotherapy drugs like oxaliplatin and 5-fluorouracil work by creating a hostile, high-stress environment that breaks down a cancer cell’s structural integrity. However, vitamin B3 supplements act as a powerful antidote to this process by significantly reducing oxidative stress within the tumor microenvironment. By reinforcing the NAD+ pathways, these supplements provide the building blocks for the cell to maintain its energy levels while simultaneously suppressing the signals that lead to cell death. This creates a defensive shield that neutralizes the very mechanism—oxidative damage—that these drugs depend on to be effective. It is a frustrating paradox where a supplement intended to support the patient’s health ends up strengthening the enemy’s biological fortifications.
Many individuals undergoing intensive treatment turn to supplements to manage exhaustion or nerve pain. What step-by-step protocols should oncology teams implement to screen for nicotinamide riboside use, and how can they explain these risks to patients without causing unnecessary alarm?
Oncology teams must transition toward a more integrated screening protocol that includes a mandatory, comprehensive review of all over-the-counter supplements during every patient intake and follow-up session. This should involve specific, non-judgmental questioning about energy-boosting vitamins like NMN and NR, which are often marketed as “natural” and therefore perceived as harmless by patients. When discussing these risks, it is vital to explain that while these vitamins might be beneficial for a healthy heart or brain, they act as a “fuel injection” for cancer cells during treatment. We need to frame the conversation around therapeutic integrity, explaining that the goal is to keep the tumor weak so the chemotherapy can do its job effectively. Emphasizing that “natural” does not always mean “safe” in the context of complex cancer biology helps patients understand that pausing these supplements is a strategic move to improve their five-year survival odds, which for pancreatic cancer remains a sobering 13%.
Pancreatic cancer presents a unique challenge where tumors are often highly resilient to traditional interventions. How does flooding the system with fuel like NMN specifically alter the tumor microenvironment, and what anecdotal evidence suggests this might be happening in clinical settings?
Pancreatic cancer is notoriously difficult to treat because its tumors are exceptionally skilled at surviving in harsh conditions, and flooding the system with NMN only exacerbates this resilience. By increasing the available NAD+ levels, we are providing these tumors with the resources they need to power up their energy systems and bypass the metabolic exhaustion that chemotherapy tries to induce. In both mouse models and laboratory experiments, we observed that the presence of these supplements directly shielded pancreatic cancer cells from the lethal effects of standard drugs. This metabolic shielding allows the tumor to remain stable or even grow despite aggressive treatment cycles. The evidence is clear: when these cells are given excess fuel, they prioritize self-repair and energy production over the cell death pathways we are trying to activate.
While certain vitamins offer genuine benefits for healthy individuals, their roles change significantly during active chemotherapy. How can researchers better distinguish between supplements that support recovery and those that inadvertently protect tumors, and what metrics should define these safety boundaries?
The distinction lies in how a supplement interacts with the specific mechanism of action of the chemotherapy being used. Researchers must focus on whether a supplement enhances the tumor’s ability to repair DNA or neutralize oxidative stress, which are the primary “safety boundaries” that define a supplement as risky. We need to define clear metrics based on whether a substance interferes with the 5-year survival rates or the immediate apoptotic response of cancer cells in clinical trials. For a healthy individual, boosting NAD+ might slow aging or protect the heart, but in an oncology patient, that same boost acts as a survival kit for the tumor. Moving forward, the safety of any supplement must be validated through the lens of tumor metabolism, ensuring that we are not inadvertently providing the very armor the cancer needs to resist our most potent therapies.
What is your forecast for the future of nutritional supplementation during active oncology treatments?
I forecast a shift toward “metabolic precision nutrition,” where supplements are strictly regulated and prescribed as part of the clinical protocol rather than left to the patient’s discretion. We will likely see a move away from the generalized use of “energy-boosting” supplements during chemotherapy, replaced by targeted interventions that have been rigorously tested for interactions with specific drug classes. The medical community is waking up to the fact that the tumor microenvironment is highly sensitive to nutritional inputs, and our discovery is a call to action for more routine screening and clinical research. Ultimately, the goal will be to synchronize a patient’s nutritional intake with their treatment schedule to ensure that we are feeding the person while simultaneously starving the tumor.
